NCT03669861View on ClinicalTrials.gov

Safety and Efficacy of Abatacept in IgG4-Related Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

April 10, 2020

Study Completion Date

November 10, 2020

Conditions

IgG4-related Disease

Interventions

DRUG

Abatacept

Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT03669861 - Safety and Efficacy of Abatacept in IgG4-Related Disease | Biotech Hunter | Biotech Hunter